-James D Griffin Researcher Activity Profile

Research Author Detailed Information 

James D Griffin Publication Rate By Year

James D Griffin has published 1 paper(s) in 1966, 1 paper(s) in 2003, 1 paper(s) in 2006, 9 paper(s) in 2007, 6 paper(s) in 2008, for a total of 18 research publications in total.

James D Jd Griffin Author Information

LAST NAME: griffin

FIRST NAME: James D

INITIALS: jd

AFFILIATION:

Papers

James D Griffin's Publication Record

1. The notch regulator MAML1 interacts with p53 and functions as a coactivator. Year Published: 2007
Division of Cancer Biology, Department of Medicine, ENH Research Institute, Feinberg School of Medicine, Northwestern University, Evanston, Illinois 60201, USA.
2. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Year Published: 2006
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA. Ellen_weisberg@dfci.harvard.edu
3. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. Year Published: 2007
Department of Physiology, National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. hbzhang2006@gmail.com
4. Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. Year Published: 2007
Department of Adult Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.
5. The transcriptional coactivator Maml1 is required for Notch2-mediated marginal zone B-cell development. Year Published: 2007
Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. lzwu@ufl.edu
6. Identification of Driver and Passenger Mutations of FLT3 by High-Throughput DNA Sequence Analysis and Functional Assessment of Candidate Alleles. Year Published: 2007
Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
7. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Year Published: 2007
Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
8. The transcriptional coactivator Maml1 is required for Notch2-mediated marginal zone B-cell development. Year Published: 2007
Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. lzwu@ufl.edu
9. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Year Published: 2007
Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
10. Community mental health services. Year Published: 1966
11. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Year Published: 2007
Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
12. Acute myeloid leukemia and acute promyelocytic leukemia. Year Published: 2003
University Hospital, Erasmus University Medical Center, Department of Hematology, The Netherlands.
13. The effects of Cirazoline, an alpha-1 adrenoreceptor agonist, on the firing rates of thermally classified anterior hypothalamic neurons in rat brain slices. Year Published: 2008
Department of Biology and Program in Neuroscience, Millington Hall, Room 116, College of William and Mary, Williamsburg, VA 23187, USA.
14. The effects of Cirazoline, an alpha-1 adrenoreceptor agonist, on the firing rates of thermally classified anterior hypothalamic neurons in rat brain slices. Year Published: 2008
Department of Biology and Program in Neuroscience, Millington Hall, Room 116, College of William and Mary, Williamsburg, VA 23187, USA.
15. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Year Published: 2008
16. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Year Published: 2008
17. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Year Published: 2008
Department of Medical Oncology/Hematologic Neoplasia, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
18. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Year Published: 2008
Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.